The FDA has approved a new testosterone gel (Fortesta) for the treatment of hypogonadism.
The FDA has approved a new testosterone gel (Fortesta) for the treatment of hypogonadism.
The gel is clear, colorless, and odorless. It is gently applied with one finger to the front and inner thighs, and not the upper body. It comes in a metered-dose pump that delivers the correct dose per complete depression.
In a 90-day, multicenter, open-label, phase III trial involving men with hypogonadism, 78% of patients using the gel had an average serum total testosterone concentration within the normal range at day 90. The most common side effect was application site reactions.
"Declining blood levels of testosterone can occur in men beginning as early as age 40," said Adrian Dobs, MD, of Johns Hopkins University School of Medicine, Baltimore, who served as principal investigator of the Fortesta gel phase III clinical trial. "The symptoms of low testosterone can be non-specific and often associated with other chronic medical problems. Fortesta gel is an important new treatment option for men who are diagnosed with low testosterone."
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.